Document Detail


The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
MedLine Citation:
PMID:  20819796     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: SSc is an autoimmune disease characterized by fibrosis of the skin and internal organs. Although the aetiology remains uncertain, many reports have suggested that IL-6 is involved in SSc pathogenesis. Tocilizumab, an anti-IL-6 receptor antibody, is an anti-arthritis medicine that works through the blockade of IL-6 functions. To examine the effect of tocilizumab on SSc, we administered tocilizumab to two SSc patients.
METHODS: Two dcSSc patients were administered tocilizumab at 8 mg/kg once a month for 6 months. One patient had pulmonary fibrosis assessed by CT and spirometry, and the other had chronic renal failure caused by scleroderma renal crisis. Their skin condition was monitored with a Vesmeter and the modified Rodnan total skin score (mRTSS). Skin biopsies were obtained before and after the tocilizumab treatment to investigate the histological changes.
RESULTS: After tocilizumab treatment, both patients showed softening of the skin with reductions of 50.7 and 55.7% in the total z-score of Vesmeter hardness and 51.9 and 23.0% in the mRTSS, respectively. Histological examination showed thinning of the collagen fibre bundles in the dermis. The creatinine clearance in the patient with chronic renal failure improved from 38 to 55 ml/min. However, the fibrotic changes in the lung in the other patient remained unchanged.
CONCLUSIONS: In the two cases of SSc that we report here, softening of the skin was observed during the treatment with tocilizumab.
Authors:
Yoshihito Shima; Yusuke Kuwahara; Hiroyuki Murota; Shun Kitaba; Mari Kawai; Toru Hirano; Junsuke Arimitsu; Masashi Narazaki; Keisuke Hagihara; Atsushi Ogata; Ichiro Katayama; Ichiro Kawase; Tadamitsu Kishimoto; Toshio Tanaka
Related Documents :
9536236 - Assignment of three chinese xeroderma pigmentosum patients to complementation group c a...
11370796 - Cutaneous reactions to chemotherapeutic agents.
534616 - Specific hyposensitization in atopic dermatitis.
19785086 - Skin diseases in patients with beta-thalassemia major.
9536236 - Assignment of three chinese xeroderma pigmentosum patients to complementation group c a...
20718946 - Perception of dysphagia: lack of correlation with objective measurements of esophageal ...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-05
Journal Detail:
Title:  Rheumatology (Oxford, England)     Volume:  49     ISSN:  1462-0332     ISO Abbreviation:  Rheumatology (Oxford)     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-15     Completed Date:  2011-09-19     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  100883501     Medline TA:  Rheumatology (Oxford)     Country:  England    
Other Details:
Languages:  eng     Pagination:  2408-12     Citation Subset:  AIM; IM    
Affiliation:
Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. ryanjin@imed3.med.osaka-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Anti-Idiotypic / immunology,  therapeutic use*
Antibodies, Monoclonal / immunology,  therapeutic use*
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / immunology,  therapeutic use*
Female
Humans
Male
Middle Aged
Receptors, Interleukin-6 / immunology,  therapeutic use*
Scleroderma, Systemic / drug therapy*,  immunology,  pathology
Severity of Illness Index
Skin / drug effects*
Chemical
Reg. No./Substance:
0/Antibodies, Anti-Idiotypic; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Receptors, Interleukin-6; 0/tocilizumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An unusual phenotype in Muckle-Wells syndrome associated with NLRP3 E311K.
Next Document:  Fatigue in rheumatoid arthritis: time for a conceptual model.